For example, in 2016, Zhao et al. found that in Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), resistance to dasatinib, a BCR-ABL1 inhibitor, can cause collateral sensitivity to crizotinib, foretinib, vandetanib, and cabozantinib—cMET and/or VEGFR inhibitors5. The gene discussed is KDR; the disease is acute lymphoblastic leukemia.